| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Failure | 135 | 2024 | 2516 | 19.080 |
Why?
|
| Cardiology | 46 | 2023 | 530 | 7.740 |
Why?
|
| American Heart Association | 46 | 2022 | 310 | 5.030 |
Why?
|
| Stroke Volume | 28 | 2023 | 577 | 3.100 |
Why?
|
| Women's Health | 5 | 2021 | 205 | 2.830 |
Why?
|
| Advisory Committees | 20 | 2022 | 203 | 2.490 |
Why?
|
| Angiotensin Receptor Antagonists | 8 | 2023 | 151 | 2.100 |
Why?
|
| Cardiovascular Diseases | 27 | 2023 | 2195 | 2.100 |
Why?
|
| Ventricular Dysfunction, Left | 9 | 2023 | 435 | 1.850 |
Why?
|
| Myocarditis | 5 | 2023 | 190 | 1.820 |
Why?
|
| Cardiomyopathies | 12 | 2023 | 610 | 1.790 |
Why?
|
| Pregnancy Complications, Cardiovascular | 5 | 2018 | 99 | 1.560 |
Why?
|
| Hospitalization | 19 | 2023 | 2083 | 1.520 |
Why?
|
| Humans | 231 | 2024 | 261506 | 1.430 |
Why?
|
| Myocardial Infarction | 11 | 2023 | 1374 | 1.410 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 7 | 2022 | 257 | 1.350 |
Why?
|
| Biomarkers | 27 | 2023 | 5047 | 1.270 |
Why?
|
| United States | 72 | 2023 | 15433 | 1.230 |
Why?
|
| Aminobutyrates | 4 | 2022 | 16 | 1.200 |
Why?
|
| Ventricular Remodeling | 8 | 2020 | 248 | 1.160 |
Why?
|
| Research Report | 9 | 2022 | 144 | 1.110 |
Why?
|
| Natriuretic Peptide, Brain | 10 | 2023 | 343 | 1.100 |
Why?
|
| Consensus | 14 | 2022 | 978 | 1.090 |
Why?
|
| Stroke | 3 | 2023 | 1144 | 1.090 |
Why?
|
| Ventricular Function, Left | 14 | 2023 | 603 | 1.070 |
Why?
|
| Renal Insufficiency, Chronic | 5 | 2023 | 787 | 1.040 |
Why?
|
| Heart Diseases | 7 | 2023 | 732 | 1.040 |
Why?
|
| Troponin I | 2 | 2018 | 127 | 1.010 |
Why?
|
| Cardiac Rehabilitation | 2 | 2021 | 23 | 0.980 |
Why?
|
| Coronavirus Infections | 7 | 2020 | 651 | 0.960 |
Why?
|
| Cardiomyopathy, Dilated | 3 | 2020 | 244 | 0.960 |
Why?
|
| Practice Guidelines as Topic | 21 | 2020 | 2403 | 0.940 |
Why?
|
| Pneumonia, Viral | 6 | 2020 | 715 | 0.930 |
Why?
|
| Peripheral Arterial Disease | 3 | 2023 | 267 | 0.900 |
Why?
|
| Concept Formation | 1 | 2023 | 32 | 0.900 |
Why?
|
| Databases, Factual | 6 | 2020 | 2218 | 0.850 |
Why?
|
| Disease Management | 15 | 2021 | 1052 | 0.850 |
Why?
|
| Cardiovascular System | 5 | 2022 | 145 | 0.850 |
Why?
|
| Valsartan | 4 | 2023 | 38 | 0.830 |
Why?
|
| Metabolic Syndrome | 4 | 2022 | 353 | 0.790 |
Why?
|
| Betacoronavirus | 4 | 2020 | 527 | 0.780 |
Why?
|
| Periodicals as Topic | 5 | 2023 | 338 | 0.770 |
Why?
|
| Evidence-Based Medicine | 10 | 2019 | 1085 | 0.760 |
Why?
|
| Prognosis | 31 | 2023 | 21713 | 0.730 |
Why?
|
| Autoantigens | 1 | 2021 | 234 | 0.730 |
Why?
|
| Spike Glycoprotein, Coronavirus | 2 | 2021 | 222 | 0.720 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 4 | 2023 | 30 | 0.720 |
Why?
|
| Adrenergic beta-Antagonists | 6 | 2023 | 323 | 0.710 |
Why?
|
| Healthcare Disparities | 4 | 2020 | 598 | 0.710 |
Why?
|
| Health Status Disparities | 3 | 2019 | 291 | 0.700 |
Why?
|
| Risk Factors | 35 | 2024 | 17523 | 0.690 |
Why?
|
| Digoxin | 2 | 2010 | 63 | 0.690 |
Why?
|
| Blood Pressure | 6 | 2021 | 1467 | 0.680 |
Why?
|
| Comorbidity | 13 | 2022 | 2352 | 0.670 |
Why?
|
| Pulmonary Wedge Pressure | 2 | 2016 | 62 | 0.660 |
Why?
|
| Clinical Trials as Topic | 14 | 2021 | 3719 | 0.640 |
Why?
|
| Peripartum Period | 5 | 2021 | 35 | 0.630 |
Why?
|
| Sex Factors | 11 | 2021 | 2139 | 0.620 |
Why?
|
| Electrocardiography | 4 | 2013 | 1145 | 0.610 |
Why?
|
| Atherosclerosis | 7 | 2023 | 935 | 0.600 |
Why?
|
| Pandemics | 7 | 2022 | 1559 | 0.600 |
Why?
|
| Societies, Medical | 8 | 2019 | 1335 | 0.590 |
Why?
|
| Risk Assessment | 16 | 2023 | 6869 | 0.590 |
Why?
|
| Atrial Pressure | 1 | 2016 | 6 | 0.570 |
Why?
|
| Heart-Assist Devices | 3 | 2023 | 1171 | 0.570 |
Why?
|
| Dyspnea | 2 | 2014 | 416 | 0.570 |
Why?
|
| Tetrazoles | 3 | 2022 | 106 | 0.560 |
Why?
|
| Heart Transplantation | 7 | 2021 | 908 | 0.550 |
Why?
|
| Acute Disease | 9 | 2023 | 2422 | 0.550 |
Why?
|
| Hyperlipidemias | 2 | 2016 | 235 | 0.550 |
Why?
|
| Female | 68 | 2023 | 141928 | 0.550 |
Why?
|
| Telemedicine | 1 | 2022 | 471 | 0.540 |
Why?
|
| Hospital Mortality | 9 | 2023 | 1274 | 0.530 |
Why?
|
| Acute Kidney Injury | 2 | 2022 | 739 | 0.530 |
Why?
|
| Obesity | 7 | 2018 | 2884 | 0.520 |
Why?
|
| Cocaine | 1 | 2017 | 233 | 0.520 |
Why?
|
| Inpatients | 1 | 2020 | 678 | 0.520 |
Why?
|
| Treatment Outcome | 33 | 2023 | 32848 | 0.510 |
Why?
|
| Drug Combinations | 3 | 2022 | 621 | 0.510 |
Why?
|
| Cardiotonic Agents | 2 | 2023 | 151 | 0.510 |
Why?
|
| Health Promotion | 1 | 2019 | 502 | 0.500 |
Why?
|
| Cocaine-Related Disorders | 1 | 2017 | 231 | 0.490 |
Why?
|
| Incidence | 11 | 2023 | 5673 | 0.490 |
Why?
|
| Chagas Cardiomyopathy | 1 | 2014 | 45 | 0.490 |
Why?
|
| Diabetes Mellitus | 4 | 2018 | 1054 | 0.490 |
Why?
|
| Cardiac Resynchronization Therapy | 2 | 2011 | 36 | 0.490 |
Why?
|
| Lung Diseases | 2 | 2014 | 717 | 0.480 |
Why?
|
| Global Health | 1 | 2019 | 657 | 0.470 |
Why?
|
| Male | 63 | 2023 | 123000 | 0.460 |
Why?
|
| Hypertension | 4 | 2021 | 1503 | 0.460 |
Why?
|
| Cardiovascular Agents | 4 | 2020 | 128 | 0.460 |
Why?
|
| Coronary Artery Bypass | 5 | 2021 | 708 | 0.460 |
Why?
|
| Diuretics | 4 | 2023 | 170 | 0.440 |
Why?
|
| Hypotension | 2 | 2012 | 210 | 0.430 |
Why?
|
| Ventricular Pressure | 2 | 2011 | 46 | 0.430 |
Why?
|
| Nervous System Diseases | 3 | 2021 | 500 | 0.430 |
Why?
|
| Neurotransmitter Agents | 2 | 2012 | 159 | 0.420 |
Why?
|
| Puerperal Disorders | 3 | 2017 | 41 | 0.420 |
Why?
|
| Propanolamines | 1 | 2011 | 44 | 0.420 |
Why?
|
| Myocardial Contraction | 2 | 2011 | 291 | 0.410 |
Why?
|
| Wolff-Parkinson-White Syndrome | 1 | 2012 | 62 | 0.410 |
Why?
|
| Quality of Life | 4 | 2022 | 4532 | 0.410 |
Why?
|
| Percutaneous Coronary Intervention | 4 | 2020 | 342 | 0.410 |
Why?
|
| ST Elevation Myocardial Infarction | 3 | 2020 | 105 | 0.400 |
Why?
|
| Severity of Illness Index | 11 | 2024 | 4320 | 0.400 |
Why?
|
| Carbazoles | 1 | 2011 | 87 | 0.400 |
Why?
|
| Vasodilator Agents | 2 | 2014 | 219 | 0.400 |
Why?
|
| Chest Pain | 1 | 2012 | 155 | 0.390 |
Why?
|
| Renin-Angiotensin System | 3 | 2020 | 103 | 0.390 |
Why?
|
| Troponin T | 4 | 2016 | 261 | 0.390 |
Why?
|
| Biphenyl Compounds | 3 | 2022 | 194 | 0.380 |
Why?
|
| Heart Valve Prosthesis Implantation | 4 | 2023 | 563 | 0.380 |
Why?
|
| Primary Prevention | 4 | 2021 | 255 | 0.380 |
Why?
|
| Chronic Disease | 6 | 2022 | 1819 | 0.380 |
Why?
|
| Acute Coronary Syndrome | 4 | 2018 | 259 | 0.370 |
Why?
|
| Perioperative Care | 4 | 2015 | 451 | 0.370 |
Why?
|
| Endpoint Determination | 3 | 2015 | 176 | 0.370 |
Why?
|
| Aged | 40 | 2023 | 70117 | 0.370 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2010 | 105 | 0.370 |
Why?
|
| Middle Aged | 45 | 2023 | 86204 | 0.370 |
Why?
|
| Sodium | 3 | 2023 | 353 | 0.360 |
Why?
|
| Patient Readmission | 4 | 2023 | 548 | 0.360 |
Why?
|
| Writing | 2 | 2021 | 104 | 0.360 |
Why?
|
| Cardiac Catheterization | 4 | 2016 | 687 | 0.350 |
Why?
|
| Diabetes Mellitus, Type 2 | 4 | 2023 | 1362 | 0.350 |
Why?
|
| Adrenergic alpha-1 Receptor Antagonists | 1 | 2009 | 28 | 0.350 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 2009 | 67 | 0.350 |
Why?
|
| Prosthesis Implantation | 1 | 2011 | 263 | 0.340 |
Why?
|
| Shock, Cardiogenic | 3 | 2023 | 228 | 0.330 |
Why?
|
| Risk Reduction Behavior | 2 | 2021 | 227 | 0.330 |
Why?
|
| Spironolactone | 2 | 2011 | 22 | 0.330 |
Why?
|
| Heart Defects, Congenital | 6 | 2019 | 1697 | 0.320 |
Why?
|
| Heart Failure, Systolic | 1 | 2008 | 32 | 0.320 |
Why?
|
| Peptide Fragments | 5 | 2023 | 1271 | 0.320 |
Why?
|
| Prostatic Hyperplasia | 1 | 2009 | 210 | 0.320 |
Why?
|
| Tumor Necrosis Factor-alpha | 6 | 2010 | 1538 | 0.320 |
Why?
|
| Diabetes Complications | 1 | 2009 | 305 | 0.310 |
Why?
|
| Time Factors | 14 | 2023 | 12926 | 0.310 |
Why?
|
| Sleep Apnea, Obstructive | 3 | 2021 | 228 | 0.310 |
Why?
|
| Artificial Intelligence | 4 | 2024 | 388 | 0.300 |
Why?
|
| Randomized Controlled Trials as Topic | 6 | 2018 | 2594 | 0.300 |
Why?
|
| Coronary Artery Disease | 5 | 2021 | 1011 | 0.300 |
Why?
|
| Health Services Needs and Demand | 2 | 2021 | 244 | 0.290 |
Why?
|
| Japan | 3 | 2021 | 227 | 0.290 |
Why?
|
| Mortality | 3 | 2016 | 343 | 0.280 |
Why?
|
| Disease Progression | 8 | 2023 | 6682 | 0.280 |
Why?
|
| Thrombolytic Therapy | 2 | 2020 | 257 | 0.280 |
Why?
|
| Inflammation | 2 | 2020 | 2522 | 0.280 |
Why?
|
| Glomerular Filtration Rate | 3 | 2022 | 602 | 0.270 |
Why?
|
| Severe Acute Respiratory Syndrome | 3 | 2020 | 82 | 0.270 |
Why?
|
| Goals | 3 | 2019 | 185 | 0.270 |
Why?
|
| Cytokines | 8 | 2021 | 2809 | 0.270 |
Why?
|
| Exercise Test | 3 | 2014 | 312 | 0.260 |
Why?
|
| Precision Medicine | 1 | 2013 | 1154 | 0.260 |
Why?
|
| Prevalence | 8 | 2023 | 3260 | 0.260 |
Why?
|
| Cause of Death | 3 | 2017 | 752 | 0.250 |
Why?
|
| Follow-Up Studies | 14 | 2017 | 14889 | 0.250 |
Why?
|
| Kidney | 2 | 2018 | 2146 | 0.250 |
Why?
|
| Echocardiography | 4 | 2023 | 1182 | 0.240 |
Why?
|
| Registries | 5 | 2019 | 2170 | 0.240 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2018 | 444 | 0.240 |
Why?
|
| Hemodynamics | 6 | 2023 | 935 | 0.230 |
Why?
|
| Peptidyl-Dipeptidase A | 2 | 2020 | 80 | 0.230 |
Why?
|
| Transitional Care | 1 | 2023 | 22 | 0.230 |
Why?
|
| Heart Valve Diseases | 2 | 2015 | 193 | 0.220 |
Why?
|
| Research Design | 5 | 2020 | 1544 | 0.220 |
Why?
|
| Receptors, Tumor Necrosis Factor | 3 | 2008 | 184 | 0.220 |
Why?
|
| Personal Protective Equipment | 2 | 2020 | 64 | 0.220 |
Why?
|
| Technology | 1 | 2023 | 96 | 0.220 |
Why?
|
| Sleep Apnea, Central | 1 | 2022 | 7 | 0.220 |
Why?
|
| China | 2 | 2021 | 606 | 0.220 |
Why?
|
| Anterior Wall Myocardial Infarction | 1 | 2022 | 13 | 0.210 |
Why?
|
| Confidence Intervals | 5 | 2010 | 756 | 0.210 |
Why?
|
| Technology Assessment, Biomedical | 1 | 2022 | 59 | 0.210 |
Why?
|
| Body Mass Index | 5 | 2018 | 2203 | 0.210 |
Why?
|
| Antihypertensive Agents | 2 | 2023 | 395 | 0.210 |
Why?
|
| Immunoglobulin G | 2 | 2008 | 1021 | 0.210 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2004 | 317 | 0.210 |
Why?
|
| Aortic Valve | 3 | 2015 | 581 | 0.200 |
Why?
|
| Hypoglycemic Agents | 4 | 2022 | 586 | 0.200 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2023 | 226 | 0.200 |
Why?
|
| Electric Stimulation Therapy | 1 | 2022 | 116 | 0.200 |
Why?
|
| Protein Precursors | 2 | 2021 | 240 | 0.200 |
Why?
|
| Complementary Therapies | 1 | 2022 | 126 | 0.200 |
Why?
|
| Molecular Mimicry | 1 | 2021 | 72 | 0.200 |
Why?
|
| Patient Selection | 5 | 2020 | 2055 | 0.200 |
Why?
|
| Healthy Lifestyle | 1 | 2021 | 44 | 0.200 |
Why?
|
| New Zealand | 1 | 2021 | 60 | 0.200 |
Why?
|
| Monitoring, Physiologic | 2 | 2022 | 502 | 0.200 |
Why?
|
| Patient Care Team | 4 | 2015 | 795 | 0.200 |
Why?
|
| Heart Function Tests | 2 | 2014 | 73 | 0.190 |
Why?
|
| Sexism | 1 | 2021 | 51 | 0.190 |
Why?
|
| Retrospective Studies | 18 | 2022 | 37905 | 0.190 |
Why?
|
| Public Opinion | 1 | 2021 | 83 | 0.190 |
Why?
|
| Educational Status | 1 | 2022 | 397 | 0.190 |
Why?
|
| Diabetic Ketoacidosis | 1 | 2022 | 136 | 0.190 |
Why?
|
| Heart Valve Prosthesis | 3 | 2013 | 386 | 0.190 |
Why?
|
| Aortic Valve Stenosis | 4 | 2014 | 476 | 0.190 |
Why?
|
| Atrial Fibrillation | 2 | 2022 | 719 | 0.190 |
Why?
|
| Myocardium | 6 | 2021 | 1313 | 0.190 |
Why?
|
| Australia | 1 | 2021 | 225 | 0.190 |
Why?
|
| Specialization | 1 | 2021 | 130 | 0.190 |
Why?
|
| Pain Management | 3 | 2015 | 668 | 0.190 |
Why?
|
| India | 1 | 2021 | 301 | 0.190 |
Why?
|
| Telemetry | 1 | 2020 | 39 | 0.180 |
Why?
|
| Shock, Septic | 1 | 2022 | 181 | 0.180 |
Why?
|
| Pregnancy | 6 | 2018 | 7573 | 0.180 |
Why?
|
| Canada | 1 | 2021 | 429 | 0.180 |
Why?
|
| Occupational Health | 1 | 2020 | 95 | 0.180 |
Why?
|
| Adult | 20 | 2023 | 77950 | 0.180 |
Why?
|
| Physicians, Women | 1 | 2021 | 105 | 0.180 |
Why?
|
| Neprilysin | 1 | 2019 | 66 | 0.180 |
Why?
|
| Enkephalins | 1 | 2019 | 23 | 0.180 |
Why?
|
| Survival Analysis | 6 | 2014 | 9180 | 0.170 |
Why?
|
| Texas | 8 | 2017 | 6311 | 0.170 |
Why?
|
| Proportional Hazards Models | 6 | 2014 | 4988 | 0.170 |
Why?
|
| Ventricular Function, Right | 2 | 2018 | 111 | 0.170 |
Why?
|
| Ethics Committees, Research | 1 | 2019 | 40 | 0.170 |
Why?
|
| Health Status | 2 | 2020 | 590 | 0.170 |
Why?
|
| Quality Indicators, Health Care | 2 | 2023 | 348 | 0.170 |
Why?
|
| Disease Transmission, Infectious | 1 | 2020 | 94 | 0.170 |
Why?
|
| Cohort Studies | 10 | 2016 | 9244 | 0.170 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2020 | 164 | 0.170 |
Why?
|
| Nurse Practitioners | 2 | 2019 | 63 | 0.170 |
Why?
|
| Standard of Care | 1 | 2020 | 243 | 0.160 |
Why?
|
| Research Support as Topic | 1 | 2019 | 122 | 0.160 |
Why?
|
| Leadership | 1 | 2021 | 254 | 0.160 |
Why?
|
| Hyponatremia | 2 | 2014 | 82 | 0.160 |
Why?
|
| Triage | 1 | 2020 | 252 | 0.160 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 1 | 2018 | 48 | 0.160 |
Why?
|
| Wearable Electronic Devices | 1 | 2020 | 105 | 0.160 |
Why?
|
| Longitudinal Studies | 1 | 2023 | 1945 | 0.160 |
Why?
|
| C-Reactive Protein | 2 | 2012 | 527 | 0.150 |
Why?
|
| Prospective Studies | 10 | 2022 | 12873 | 0.150 |
Why?
|
| Research Personnel | 1 | 2019 | 156 | 0.150 |
Why?
|
| Social Media | 1 | 2021 | 203 | 0.150 |
Why?
|
| Quality of Health Care | 4 | 2015 | 621 | 0.150 |
Why?
|
| Machine Learning | 1 | 2020 | 319 | 0.150 |
Why?
|
| Population Surveillance | 1 | 2021 | 627 | 0.150 |
Why?
|
| Myocardial Ischemia | 2 | 2014 | 435 | 0.150 |
Why?
|
| Patient Discharge | 5 | 2022 | 661 | 0.150 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2022 | 421 | 0.150 |
Why?
|
| Glucose | 1 | 2023 | 1248 | 0.150 |
Why?
|
| Virus Diseases | 1 | 2020 | 398 | 0.140 |
Why?
|
| Endovascular Procedures | 2 | 2013 | 516 | 0.140 |
Why?
|
| Hepatomegaly | 1 | 2016 | 69 | 0.140 |
Why?
|
| Continuous Positive Airway Pressure | 2 | 2015 | 80 | 0.140 |
Why?
|
| Relaxin | 1 | 2016 | 21 | 0.140 |
Why?
|
| Heart | 2 | 2022 | 1223 | 0.140 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 524 | 0.140 |
Why?
|
| Terminology as Topic | 3 | 2015 | 414 | 0.140 |
Why?
|
| Behavior Therapy | 1 | 2018 | 298 | 0.140 |
Why?
|
| History, 21st Century | 2 | 2020 | 441 | 0.140 |
Why?
|
| Cardiac Surgical Procedures | 2 | 2020 | 1237 | 0.140 |
Why?
|
| Prolactin | 1 | 2016 | 155 | 0.130 |
Why?
|
| Inflammation Mediators | 2 | 2017 | 423 | 0.130 |
Why?
|
| Maximum Tolerated Dose | 1 | 2019 | 1290 | 0.130 |
Why?
|
| Ultrasonography | 2 | 2012 | 1863 | 0.130 |
Why?
|
| Enzyme Inhibitors | 1 | 2023 | 1879 | 0.130 |
Why?
|
| Critical Care | 1 | 2021 | 770 | 0.130 |
Why?
|
| Ascites | 1 | 2016 | 198 | 0.130 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2016 | 125 | 0.130 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2021 | 1209 | 0.130 |
Why?
|
| Cross-Sectional Studies | 4 | 2022 | 4314 | 0.130 |
Why?
|
| Veterans | 3 | 2023 | 1641 | 0.130 |
Why?
|
| Procollagen | 1 | 2014 | 31 | 0.130 |
Why?
|
| Exercise | 2 | 2021 | 1183 | 0.130 |
Why?
|
| Health Personnel | 1 | 2020 | 625 | 0.120 |
Why?
|
| Tachycardia, Supraventricular | 1 | 2015 | 84 | 0.120 |
Why?
|
| Physician Assistants | 1 | 2015 | 74 | 0.120 |
Why?
|
| Lower Extremity | 1 | 2017 | 299 | 0.120 |
Why?
|
| Edema | 1 | 2016 | 267 | 0.120 |
Why?
|
| Rheumatic Fever | 1 | 2014 | 18 | 0.120 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2017 | 582 | 0.120 |
Why?
|
| Obesity, Morbid | 1 | 2017 | 224 | 0.120 |
Why?
|
| Time-to-Treatment | 1 | 2016 | 292 | 0.120 |
Why?
|
| Secondary Prevention | 4 | 2018 | 329 | 0.120 |
Why?
|
| Observational Studies as Topic | 1 | 2014 | 140 | 0.120 |
Why?
|
| Fibrinolytic Agents | 1 | 2016 | 324 | 0.120 |
Why?
|
| Hypercholesterolemia | 2 | 2013 | 259 | 0.120 |
Why?
|
| Mitral Valve Insufficiency | 2 | 2014 | 180 | 0.120 |
Why?
|
| Case-Control Studies | 5 | 2021 | 6100 | 0.120 |
Why?
|
| Patient Care Management | 1 | 2014 | 94 | 0.120 |
Why?
|
| beta-Thalassemia | 1 | 2013 | 17 | 0.120 |
Why?
|
| Hospitals, Veterans | 2 | 2013 | 397 | 0.120 |
Why?
|
| Monocytes | 1 | 2017 | 788 | 0.120 |
Why?
|
| Survival Rate | 6 | 2017 | 12221 | 0.110 |
Why?
|
| Collagen Type I | 1 | 2014 | 204 | 0.110 |
Why?
|
| Coronary Angiography | 1 | 2016 | 598 | 0.110 |
Why?
|
| Foundations | 1 | 2013 | 26 | 0.110 |
Why?
|
| Guideline Adherence | 4 | 2018 | 636 | 0.110 |
Why?
|
| Myocardial Revascularization | 1 | 2014 | 134 | 0.110 |
Why?
|
| Life Style | 2 | 2013 | 612 | 0.110 |
Why?
|
| Hypertension, Pulmonary | 2 | 2018 | 462 | 0.110 |
Why?
|
| Sex Characteristics | 2 | 2021 | 417 | 0.110 |
Why?
|
| Hypoxia | 1 | 2015 | 443 | 0.110 |
Why?
|
| Weight Reduction Programs | 1 | 2013 | 78 | 0.110 |
Why?
|
| Phenotype | 3 | 2021 | 6295 | 0.110 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2019 | 581 | 0.110 |
Why?
|
| Interleukin-6 | 3 | 2020 | 1038 | 0.110 |
Why?
|
| Blood Urea Nitrogen | 1 | 2012 | 95 | 0.110 |
Why?
|
| Coronary Disease | 1 | 2016 | 764 | 0.110 |
Why?
|
| Editorial Policies | 2 | 2023 | 87 | 0.110 |
Why?
|
| Killer Cells, Natural | 1 | 2017 | 904 | 0.110 |
Why?
|
| Lab-On-A-Chip Devices | 1 | 2012 | 25 | 0.100 |
Why?
|
| Multivariate Analysis | 3 | 2009 | 4298 | 0.100 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2014 | 849 | 0.100 |
Why?
|
| Nanomedicine | 1 | 2012 | 54 | 0.100 |
Why?
|
| Biomedical Research | 1 | 2019 | 806 | 0.100 |
Why?
|
| Vocabulary | 1 | 2011 | 23 | 0.100 |
Why?
|
| Diffusion of Innovation | 1 | 2013 | 160 | 0.100 |
Why?
|
| Endocardium | 2 | 2021 | 50 | 0.100 |
Why?
|
| Models, Cardiovascular | 2 | 2011 | 202 | 0.100 |
Why?
|
| Statistics as Topic | 1 | 2012 | 445 | 0.100 |
Why?
|
| Death, Sudden, Cardiac | 2 | 2023 | 253 | 0.100 |
Why?
|
| Central Venous Pressure | 1 | 2011 | 28 | 0.100 |
Why?
|
| Program Development | 1 | 2012 | 261 | 0.100 |
Why?
|
| Physicians | 2 | 2019 | 882 | 0.100 |
Why?
|
| General Surgery | 1 | 2014 | 326 | 0.100 |
Why?
|
| Anticholesteremic Agents | 1 | 2013 | 256 | 0.100 |
Why?
|
| Outpatients | 1 | 2014 | 462 | 0.100 |
Why?
|
| Predictive Value of Tests | 5 | 2020 | 4892 | 0.100 |
Why?
|
| Systole | 1 | 2011 | 196 | 0.100 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2011 | 136 | 0.090 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2012 | 314 | 0.090 |
Why?
|
| Blood Sedimentation | 1 | 2010 | 35 | 0.090 |
Why?
|
| Viral Tropism | 2 | 2020 | 40 | 0.090 |
Why?
|
| Preventive Health Services | 1 | 2010 | 75 | 0.090 |
Why?
|
| Cholesterol, HDL | 1 | 2011 | 341 | 0.090 |
Why?
|
| Hospital Costs | 2 | 2022 | 228 | 0.090 |
Why?
|
| Overweight | 1 | 2013 | 484 | 0.090 |
Why?
|
| Forecasting | 1 | 2013 | 694 | 0.090 |
Why?
|
| Aged, 80 and over | 9 | 2020 | 29902 | 0.090 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2016 | 1533 | 0.090 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2018 | 1303 | 0.090 |
Why?
|
| Point-of-Care Systems | 1 | 2012 | 196 | 0.090 |
Why?
|
| Receptors, Adrenergic, alpha-1 | 1 | 2009 | 39 | 0.090 |
Why?
|
| Diagnostic Imaging | 2 | 2014 | 1162 | 0.090 |
Why?
|
| Sexual Behavior | 1 | 2012 | 310 | 0.090 |
Why?
|
| Immunoglobulins, Intravenous | 2 | 2020 | 180 | 0.090 |
Why?
|
| Young Adult | 6 | 2020 | 21445 | 0.080 |
Why?
|
| Biopsy | 3 | 2021 | 3443 | 0.080 |
Why?
|
| Chemokines | 1 | 2010 | 314 | 0.080 |
Why?
|
| Haemophilus Infections | 1 | 2009 | 103 | 0.080 |
Why?
|
| Internal Mammary-Coronary Artery Anastomosis | 1 | 2008 | 24 | 0.080 |
Why?
|
| Haemophilus influenzae | 1 | 2009 | 144 | 0.080 |
Why?
|
| Medical Records | 1 | 2009 | 415 | 0.080 |
Why?
|
| Peptides | 1 | 2014 | 1479 | 0.080 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2023 | 473 | 0.080 |
Why?
|
| Cholesterol | 1 | 2011 | 658 | 0.080 |
Why?
|
| Clinical Competence | 2 | 2013 | 1270 | 0.080 |
Why?
|
| Pneumonia, Bacterial | 1 | 2009 | 130 | 0.080 |
Why?
|
| Coronary Vessels | 1 | 2012 | 665 | 0.080 |
Why?
|
| Cultural Diversity | 1 | 2008 | 76 | 0.080 |
Why?
|
| Analysis of Variance | 1 | 2012 | 2307 | 0.080 |
Why?
|
| Cholesterol, LDL | 1 | 2011 | 565 | 0.080 |
Why?
|
| Age Factors | 4 | 2020 | 5377 | 0.080 |
Why?
|
| Odds Ratio | 2 | 2009 | 2316 | 0.080 |
Why?
|
| Early Diagnosis | 2 | 2023 | 298 | 0.080 |
Why?
|
| Cluster Analysis | 1 | 2010 | 1053 | 0.080 |
Why?
|
| Streptococcus pneumoniae | 1 | 2009 | 330 | 0.070 |
Why?
|
| Seasons | 1 | 2008 | 340 | 0.070 |
Why?
|
| Recurrence | 2 | 2012 | 4758 | 0.070 |
Why?
|
| Metformin | 1 | 2010 | 378 | 0.070 |
Why?
|
| Anemia | 2 | 2021 | 689 | 0.070 |
Why?
|
| Thiazolidinediones | 1 | 2007 | 148 | 0.070 |
Why?
|
| Etanercept | 2 | 2008 | 54 | 0.070 |
Why?
|
| Cardiac Pacing, Artificial | 1 | 2006 | 127 | 0.070 |
Why?
|
| Heart Rate | 2 | 2006 | 737 | 0.070 |
Why?
|
| Cardiac Output | 2 | 2020 | 194 | 0.070 |
Why?
|
| Common Data Elements | 2 | 2015 | 5 | 0.070 |
Why?
|
| Length of Stay | 3 | 2021 | 1900 | 0.070 |
Why?
|
| Matrix Metalloproteinases | 2 | 2002 | 143 | 0.060 |
Why?
|
| Fellowships and Scholarships | 1 | 2009 | 390 | 0.060 |
Why?
|
| Heart Arrest | 2 | 2020 | 358 | 0.060 |
Why?
|
| Attitude of Health Personnel | 1 | 2011 | 918 | 0.060 |
Why?
|
| Staphylococcus aureus | 1 | 2009 | 548 | 0.060 |
Why?
|
| Reproducibility of Results | 4 | 2020 | 6009 | 0.060 |
Why?
|
| Heart Ventricles | 2 | 2020 | 846 | 0.060 |
Why?
|
| Information Technology | 1 | 2024 | 12 | 0.060 |
Why?
|
| Heart Atria | 1 | 2006 | 352 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2014 | 6207 | 0.060 |
Why?
|
| Evidence-Based Practice | 2 | 2015 | 117 | 0.060 |
Why?
|
| Electronic Health Records | 1 | 2011 | 929 | 0.060 |
Why?
|
| Models, Statistical | 1 | 2009 | 1171 | 0.060 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2023 | 112 | 0.060 |
Why?
|
| Staphylococcal Infections | 1 | 2009 | 672 | 0.060 |
Why?
|
| Tissue Inhibitor of Metalloproteinases | 1 | 2002 | 43 | 0.060 |
Why?
|
| Antiviral Agents | 2 | 2020 | 1230 | 0.060 |
Why?
|
| Equipment Design | 2 | 2020 | 1204 | 0.050 |
Why?
|
| Diagnosis, Differential | 1 | 2012 | 4744 | 0.050 |
Why?
|
| Animals | 10 | 2021 | 59536 | 0.050 |
Why?
|
| Bacteremia | 1 | 2009 | 689 | 0.050 |
Why?
|
| Sodium-Glucose Transporter 2 | 1 | 2022 | 15 | 0.050 |
Why?
|
| Receptors, Cytokine | 2 | 2000 | 176 | 0.050 |
Why?
|
| Blood Coagulation Disorders | 1 | 2004 | 120 | 0.050 |
Why?
|
| Return to Sport | 1 | 2022 | 8 | 0.050 |
Why?
|
| Policy | 1 | 2022 | 49 | 0.050 |
Why?
|
| Norepinephrine | 1 | 2003 | 272 | 0.050 |
Why?
|
| Respiratory Function Tests | 1 | 2003 | 318 | 0.050 |
Why?
|
| Adolescent | 4 | 2019 | 31252 | 0.050 |
Why?
|
| Calcium Channel Blockers | 1 | 2022 | 135 | 0.050 |
Why?
|
| Metabolic Diseases | 1 | 2003 | 130 | 0.050 |
Why?
|
| Hyperkalemia | 1 | 2003 | 79 | 0.050 |
Why?
|
| Ambulatory Care Facilities | 1 | 2024 | 289 | 0.050 |
Why?
|
| Patient Safety | 2 | 2020 | 649 | 0.050 |
Why?
|
| Public Health Surveillance | 1 | 2021 | 63 | 0.050 |
Why?
|
| Academic Medical Centers | 2 | 2019 | 672 | 0.050 |
Why?
|
| Echovirus Infections | 1 | 2020 | 2 | 0.050 |
Why?
|
| Coxsackievirus Infections | 1 | 2020 | 17 | 0.050 |
Why?
|
| Erythema Infectiosum | 1 | 2020 | 11 | 0.050 |
Why?
|
| Double-Blind Method | 2 | 2011 | 2588 | 0.050 |
Why?
|
| Data Mining | 1 | 2021 | 88 | 0.050 |
Why?
|
| Surgical Procedures, Operative | 2 | 2015 | 383 | 0.050 |
Why?
|
| Hospitals, Rural | 1 | 2020 | 6 | 0.050 |
Why?
|
| Hospital Bed Capacity | 1 | 2020 | 27 | 0.050 |
Why?
|
| Nursing Homes | 1 | 2021 | 99 | 0.050 |
Why?
|
| Anti-HIV Agents | 1 | 2004 | 350 | 0.050 |
Why?
|
| Delphi Technique | 1 | 2021 | 210 | 0.050 |
Why?
|
| Roseolovirus Infections | 1 | 2020 | 39 | 0.050 |
Why?
|
| Cloud Computing | 1 | 2020 | 16 | 0.050 |
Why?
|
| Hospitals, Urban | 1 | 2020 | 87 | 0.050 |
Why?
|
| Blood Pressure Determination | 1 | 2020 | 109 | 0.050 |
Why?
|
| Smartphone | 1 | 2020 | 34 | 0.050 |
Why?
|
| Th17 Cells | 1 | 2021 | 162 | 0.040 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 58 | 0.040 |
Why?
|
| Education, Medical, Continuing | 2 | 2012 | 251 | 0.040 |
Why?
|
| Hospitals, Teaching | 1 | 2020 | 120 | 0.040 |
Why?
|
| HIV Infections | 2 | 2020 | 2134 | 0.040 |
Why?
|
| Receptors, Virus | 1 | 2020 | 157 | 0.040 |
Why?
|
| Contracts | 1 | 2019 | 11 | 0.040 |
Why?
|
| Motor Activity | 2 | 2013 | 693 | 0.040 |
Why?
|
| Immunization, Passive | 1 | 2020 | 172 | 0.040 |
Why?
|
| Perioperative Period | 1 | 2020 | 155 | 0.040 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2022 | 340 | 0.040 |
Why?
|
| Quality Assurance, Health Care | 2 | 2015 | 585 | 0.040 |
Why?
|
| Risk | 1 | 2004 | 1972 | 0.040 |
Why?
|
| Symptom Assessment | 1 | 2021 | 267 | 0.040 |
Why?
|
| Drug Approval | 1 | 2020 | 178 | 0.040 |
Why?
|
| Autoimmunity | 1 | 2020 | 263 | 0.040 |
Why?
|
| Serine Endopeptidases | 1 | 2020 | 275 | 0.040 |
Why?
|
| Postoperative Hemorrhage | 1 | 2020 | 162 | 0.040 |
Why?
|
| Research | 1 | 2021 | 415 | 0.040 |
Why?
|
| Organ Specificity | 1 | 2020 | 699 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 2021 | 538 | 0.040 |
Why?
|
| Europe | 1 | 2020 | 649 | 0.040 |
Why?
|
| Nurses | 1 | 2019 | 80 | 0.040 |
Why?
|
| Leukocytes | 1 | 2020 | 422 | 0.040 |
Why?
|
| Liver Diseases | 1 | 2003 | 574 | 0.040 |
Why?
|
| Blood Glucose | 1 | 2022 | 1244 | 0.040 |
Why?
|
| Ambulatory Care | 2 | 2015 | 554 | 0.040 |
Why?
|
| Kidney Diseases | 1 | 2003 | 691 | 0.040 |
Why?
|
| History, 20th Century | 1 | 2020 | 574 | 0.040 |
Why?
|
| Reference Values | 2 | 2011 | 1099 | 0.040 |
Why?
|
| Communication | 1 | 2024 | 876 | 0.040 |
Why?
|
| Mass Screening | 2 | 2021 | 1509 | 0.040 |
Why?
|
| Continuity of Patient Care | 1 | 2019 | 225 | 0.040 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2001 | 521 | 0.040 |
Why?
|
| Weight Loss | 1 | 2021 | 627 | 0.040 |
Why?
|
| Informed Consent | 1 | 2020 | 419 | 0.040 |
Why?
|
| Leptin | 1 | 2018 | 295 | 0.040 |
Why?
|
| Blood Transfusion | 1 | 2020 | 583 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2008 | 10001 | 0.040 |
Why?
|
| Cytomegalovirus Infections | 1 | 2020 | 462 | 0.040 |
Why?
|
| Immunologic Factors | 1 | 2020 | 649 | 0.040 |
Why?
|
| Congresses as Topic | 1 | 2018 | 298 | 0.040 |
Why?
|
| Tachycardia, Ventricular | 1 | 2019 | 239 | 0.030 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2020 | 489 | 0.030 |
Why?
|
| Turkey | 1 | 2015 | 57 | 0.030 |
Why?
|
| Classification | 1 | 2015 | 41 | 0.030 |
Why?
|
| Health Insurance Portability and Accountability Act | 1 | 2015 | 23 | 0.030 |
Why?
|
| Drug Prescriptions | 1 | 2018 | 289 | 0.030 |
Why?
|
| Immunity, Cellular | 1 | 2017 | 419 | 0.030 |
Why?
|
| Drug-Eluting Stents | 1 | 2016 | 131 | 0.030 |
Why?
|
| Hepatitis C | 1 | 2020 | 524 | 0.030 |
Why?
|
| Confidentiality | 1 | 2015 | 127 | 0.030 |
Why?
|
| Aspirin | 1 | 2018 | 455 | 0.030 |
Why?
|
| Pharyngitis | 1 | 2014 | 41 | 0.030 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2014 | 66 | 0.030 |
Why?
|
| Dietary Supplements | 1 | 2018 | 558 | 0.030 |
Why?
|
| Mitral Valve Stenosis | 1 | 2014 | 50 | 0.030 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2015 | 107 | 0.030 |
Why?
|
| Anthropometry | 1 | 2014 | 269 | 0.030 |
Why?
|
| Iron Chelating Agents | 1 | 2013 | 33 | 0.030 |
Why?
|
| Pericardial Effusion | 1 | 2014 | 118 | 0.030 |
Why?
|
| Iron Overload | 1 | 2013 | 35 | 0.030 |
Why?
|
| Surveys and Questionnaires | 2 | 2019 | 5687 | 0.030 |
Why?
|
| Patient Education as Topic | 1 | 2018 | 748 | 0.030 |
Why?
|
| Diet, Reducing | 1 | 2013 | 87 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2014 | 495 | 0.030 |
Why?
|
| Aortic Diseases | 1 | 2015 | 206 | 0.030 |
Why?
|
| Influenza, Human | 1 | 2020 | 925 | 0.030 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2014 | 360 | 0.030 |
Why?
|
| Cooperative Behavior | 1 | 2014 | 313 | 0.030 |
Why?
|
| Algorithms | 2 | 2016 | 3890 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2018 | 2315 | 0.030 |
Why?
|
| Recovery of Function | 1 | 2016 | 703 | 0.030 |
Why?
|
| Equipment Failure | 1 | 2013 | 191 | 0.030 |
Why?
|
| Cardiovascular Surgical Procedures | 1 | 2012 | 53 | 0.030 |
Why?
|
| Aortic Valve Insufficiency | 1 | 2014 | 167 | 0.030 |
Why?
|
| Public Policy | 1 | 2012 | 60 | 0.030 |
Why?
|
| Decision Making | 1 | 2019 | 1287 | 0.030 |
Why?
|
| Logistic Models | 2 | 2009 | 3441 | 0.030 |
Why?
|
| Angiography | 1 | 2013 | 360 | 0.030 |
Why?
|
| Streptococcal Infections | 1 | 2014 | 280 | 0.020 |
Why?
|
| Patients | 1 | 2013 | 245 | 0.020 |
Why?
|
| Quality Improvement | 1 | 2018 | 851 | 0.020 |
Why?
|
| Family Practice | 1 | 2011 | 125 | 0.020 |
Why?
|
| Delivery of Health Care | 1 | 2018 | 860 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2017 | 3033 | 0.020 |
Why?
|
| Internal Medicine | 1 | 2011 | 124 | 0.020 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2013 | 500 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 2012 | 460 | 0.020 |
Why?
|
| Pulmonary Circulation | 1 | 2011 | 131 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2015 | 2074 | 0.020 |
Why?
|
| Health Services Research | 1 | 2011 | 233 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2020 | 2330 | 0.020 |
Why?
|
| Endocrinology | 1 | 2011 | 139 | 0.020 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2012 | 605 | 0.020 |
Why?
|
| Triglycerides | 1 | 2011 | 603 | 0.020 |
Why?
|
| Pneumonia, Pneumococcal | 1 | 2009 | 74 | 0.020 |
Why?
|
| Efficiency | 1 | 2009 | 99 | 0.020 |
Why?
|
| Solubility | 1 | 2008 | 242 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2014 | 899 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2016 | 4971 | 0.020 |
Why?
|
| Palliative Care | 1 | 2019 | 2037 | 0.020 |
Why?
|
| Emergency Service, Hospital | 1 | 2015 | 1148 | 0.020 |
Why?
|
| Collagen | 1 | 2011 | 752 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2020 | 7222 | 0.020 |
Why?
|
| Protein Stability | 1 | 2008 | 370 | 0.020 |
Why?
|
| Electrooculography | 1 | 2006 | 13 | 0.020 |
Why?
|
| Community-Acquired Infections | 1 | 2009 | 285 | 0.020 |
Why?
|
| Electromyography | 1 | 2006 | 226 | 0.020 |
Why?
|
| Polysomnography | 1 | 2006 | 155 | 0.020 |
Why?
|
| Diet | 1 | 2013 | 1440 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2021 | 5542 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2008 | 1323 | 0.020 |
Why?
|
| Prosthesis Failure | 1 | 2006 | 206 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 2009 | 717 | 0.020 |
Why?
|
| Electroencephalography | 1 | 2006 | 898 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2007 | 3472 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2002 | 1764 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2007 | 4938 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2012 | 8223 | 0.010 |
Why?
|
| Interleukin-1 | 1 | 1999 | 461 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2013 | 7551 | 0.010 |
Why?
|
| Infant | 1 | 2012 | 13310 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2012 | 16273 | 0.010 |
Why?
|
| Child | 1 | 2012 | 29154 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 1999 | 4053 | 0.000 |
Why?
|
| Signal Transduction | 1 | 2002 | 11965 | 0.000 |
Why?
|